Biocon sees a sweet spot with its affordable insulin in US

The biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologics is chasing a revenue target of $1 billion in financial year 2021-22. In the previous fiscal year, its revenue had topped $200 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Lp6iaU
via IFTTT